About
Mohamed Amine Bayar, PhD
Biostatistician. Clinical development. AI/ML practitioner.
13 years across the full clinical development lifecycle — from Phase I dose escalation to Phase III pivotal trials, from SAP authorship to health authority interactions.
13+
Years of Experience
I–IV
Trial Phases
15+
Publications
1,200+
Citations
Where I've worked:
Johnson & Johnson
Lead biostatistician on multiple myeloma bispecifics, a first-in-class trispecific antibody, and CAR-T therapies. Designed and reported pivotal studies in one of the most competitive spaces in oncology.
Novartis
Core statistical contributor to the asciminib (Scemblix) program for CML, supporting both FDA and EMA marketing approvals.
Gustave Roussy
Europe's largest cancer center. Academic research at the intersection of biostatistics, genomics, and clinical outcomes.
What sets me apart:
Co-inventor of a patent applying machine learning to predict prognosis in triple-negative breast cancer. Author of 15+ peer-reviewed publications with over 1,200 citations in journals including the Annals of Oncology, JCO, and Statistics in Medicine. PhD from Université Paris-Saclay focused on Phase III trial design in rare diseases and biomarker-defined subgroups.
I don't just analyze clinical data. I understand where it comes from, what it means clinically, and what regulators need to see.